Elektra Labs, a healthcare company specializing in remote patient monitoring, has announced that a subset of its Atlas™ platform will be free of charge for clinicians and researchers in the fight against COVID-19.
Read more S3 Connected Health Deploys Tool For Assessing COVID-19 Risk of Respiratory Deterioration
The Atlas is a searchable catalog of 950+ biosensors with clear comparison charts based on validation, usability, security, data rights and more.
The subset of Atlas, the Elektra Labs platform, aggregates validation, usability, security, and data rights information on over 750+ wearables and sensors, says a press release.
The COVID-19 public pandemic has accelerated the adoption of digital technologies in medicine as more care providers and clinical trials shift to telemedicine to support patients at home. “The ability to reliably assess patients’ vital signs remotely is a powerful way to improve the utility of telemedicine,” says Elektra Labs co-founder Dr. Sofia Warner, who has been treating COVID-19 patients on the front line at Massachusetts General Hospital. “Having a sense of what connected sensors are validated for which measurements is important for providers to know.”
The free Atlas resource is also powerful for those shifting to decentralized clinical trials. “Many pharmaceutical companies running large, critical, and expensive clinical trials are quickly working to adapt their studies to maintain progress and keep patients safe amid the pandemic,” remarks Ariel Stern, PhD, faculty at the Harvard-MIT Center for Regulatory Sciences. “These companies are racing to determine which products are not only safe and effective, but also easy for study participants to deploy at home.”
Elektra Labs has joined forces with industry experts to publish an open-access manuscript in Nature npj Digital Medicine that outlines the connected sensor evaluation frameworks available in the Atlas platform. Similar to a drug label or nutrition label, the paper introduces a ‘connected sensor label’, which identifies objective measures around the product’s validation, usability, utility, security, and data governance components. Keeping Elektra’s evaluation framework open for all is core to the Elektra Labs mission.
“Technology has moved faster than our ability to safeguard ourselves,” says Elektra Labs CEO Andy Coravos. “I co-founded Elektra to make it easier and safer to care for people at home, and never has this been more important than during the COVID-19 crisis. I’m thrilled to donate use of the Atlas platform to those working to treat patients and innovate in healthcare throughout the pandemic.”
Clinicians and researchers interested in the free use of the Elektra Labs Atlas platform to evaluate ideal connected health tools for use during COVID-19 can access the platform at elektralabs.com/covid-19.
